Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
about
Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humansEssential thrombocythemiaJAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatinJanus kinases in immune cell signalingThe molecular mechanisms that control thrombopoiesisPlatelet genomics and proteomics in human health and disease.Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasmsJAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosisVenous thromboembolic diseaseReticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapyGenetic characterization of TET1, TET2, and TET3 alterations in myeloid malignanciesMolecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarraySelectivity and therapeutic inhibition of kinases: to be or not to be?Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disordersTherapeutic targeting of Janus kinasesAbnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosisThe diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markersTransformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptorHighly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarraysErythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathwayErlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growthSuppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivoRecent advances in understanding myelofibrosis and essential thrombocythemiaGenomic diversity in myeloproliferative neoplasms: focus on myelofibrosisGenomic landscape of megakaryopoiesis and platelet function defectsBudd-Chiari syndromeBlast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factorsHSP90 and HSP70: Implication in Inflammation Processes and Therapeutic Approaches for Myeloproliferative NeoplasmsCytokine Regulation of Microenvironmental Cells in Myeloproliferative NeoplasmsThe Role of Reactive Oxygen Species in Myelofibrosis and Related NeoplasmsChronic neutrophilic leukemia: a clinical perspectiveJAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indicationsPolycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617FClinical potential of pacritinib in the treatment of myelofibrosisAcute Myeloid Leukemia and Other Types of Disease Progression in Myeloproliferative NeoplasmsGenetics of myeloproliferative neoplasmsClinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challengesTargeting JAK2 in the therapy of myeloproliferative neoplasmsIntegrating non-coding RNAs in JAK-STAT regulatory networks
P2860
Q21133609-6C415089-992A-4877-BAB6-BD1EC2CFEF24Q21202968-D2CC761A-2944-4385-925A-310832224975Q24318979-67F47978-18CE-41E6-B523-3DB7D5DFA55CQ24322021-6187124A-1FE3-4B86-8B17-41AF90A1D8C7Q24536138-131739E3-4736-4FEA-B462-82A194C60F20Q24536151-E90A5280-613E-4213-83EE-B0AF573375B6Q24568313-EF38EC7B-3E5E-4950-AC7A-DBCA42AE474FQ24595117-BCE50129-D245-43AA-8F58-C6F453ED3DA2Q24609999-CBBD4057-2D46-45C4-BB9D-870E29A11634Q24631121-C4C83BAA-14BE-4138-ACC6-AADA3ED47260Q24631288-C6C9F822-1CE1-48AB-9BB8-C7CA9284EECEQ24648438-61AB8841-AB4C-40B4-907F-7F79413F0AF5Q24650855-F067DABB-5BD6-4C25-89B7-0611D3D4947FQ24656006-F601444C-B523-42C3-AB40-837D85565574Q24657681-AE526552-C5BD-4F6F-9FAF-5A768A2E8014Q24658483-AC61A7A0-31C9-489F-9606-23445EA59A70Q24671505-01B5B8C2-DFF7-4B00-8DB4-334C21C41ED6Q24675681-C383262A-AD13-4AB7-B30A-6D6FAAB1CDD2Q24676526-7D778A19-2EA6-4FE1-BCF6-8AA01CF8CD28Q24676798-956F4651-DA65-47D8-9400-C25448A1A3D1Q24685447-20A77FBD-A822-4A73-9D73-0C1617CDA5C2Q24685474-C4801D60-178A-433E-A6D5-1CD6FE457C4FQ24685620-33A3E0BF-776E-42DD-AC19-FEA1504C1A24Q26748543-2EAC815E-299E-446B-B8D6-E4DBD8E5898EQ26770330-A4E4FB69-EAFB-4AC0-9554-8C1A169D3ED4Q26770869-6BFA226B-9ACD-4416-B505-4DA3834773F2Q26775796-36C8E38B-9426-46F5-B8C4-1389A954DA72Q26777265-6DCBA4AA-FF8E-417F-BDB4-83CEFF9FE16FQ26778548-4EFD1954-9F98-4EFE-B0C9-F7DF12E9A72EQ26778929-DB016F8B-D380-4CF5-8325-D0E1F3BEA5E8Q26779929-869EE915-6438-4188-AB0B-26608B384CB4Q26781167-022210F6-23CB-4556-8152-1919F5D973FFQ26782539-C20B50C3-E4F5-4AF4-BF9B-2D4D9349108BQ26795666-57F29B67-248E-4F1E-898C-B363C31EB429Q26796450-AF5526A8-68A3-49B6-95DE-2A1CC70D8F83Q26799790-C93C86AF-DD03-4CFA-8B66-CD874F623E10Q26823651-67875548-3869-4E55-8DCB-3ECC7E43A2B9Q26823978-57805212-F1B4-47FC-9C54-FDEA708F81DDQ26860796-5DA9C157-4029-4ABF-B401-0FBE311BF731Q26863279-AC9E330E-390C-4E71-A64F-DB2BDB3A9A5B
P2860
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
@ast
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
@en
type
label
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
@ast
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
@en
prefLabel
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
@ast
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
@en
P2093
P3181
P1433
P1476
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
@en
P2093
Campbell PJ
Fourouclas N
P304
P3181
P356
10.1016/S0140-6736(05)71142-9
P407
P577
2005-03-01T00:00:00Z